NCT07469969

Brief Summary

This study is a prospective, multicenter, randomized, controlled, open-label clinical trial designed to evaluate the superiority of transauricular vagus nerve microcurrent stimulation (taVNS) combined with Tailor-Made Notched Music Training (TMNMT) compared with Tinnitus Retraining Therapy (TRT) in patients with chronic subjective tinnitus. A total of 386 participants aged 18-70 years with a tinnitus duration of at least 6 months and a Tinnitus Handicap Inventory (THI) score ≥38 will be enrolled, excluding individuals with severe hearing loss, organic cranial diseases, or other contraindications. Eligible participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group. The control group will receive standardized TRT, including habituation sound therapy and structured educational counseling, while the experimental group will receive TMNMT combined with taVNS (0.1 Hz pulse-train stimulation, sub-pain threshold intensity of 0.5-10 mA). Although the trial is open-label, outcome assessors and statisticians will remain blinded to group allocation. Baseline and follow-up assessments include THI, visual analog scale (VAS), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), audiological evaluations, and multimodal neuroimaging using EEG and fMRI. The primary outcome is the tinnitus improvement response rate at 3 months after treatment initiation, defined as a reduction of more than 7 points in the THI score from baseline. Secondary outcomes include treatment response rates at 6 and 12 months, changes in tinnitus severity and tinnitus-related comorbid symptoms, and neuroplasticity-related changes in central neural mechanisms.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
386

participants targeted

Target at P75+ for not_applicable

Timeline
44mo left

Started Apr 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Apr 2026Mar 2030

First Submitted

Initial submission to the registry

January 20, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 13, 2026

Completed
19 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2030

Last Updated

March 13, 2026

Status Verified

March 1, 2026

Enrollment Period

4 years

First QC Date

January 20, 2026

Last Update Submit

March 9, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Tinnitus Improvement Response Rate

    The Tinnitus Improvement Response Rate is evaluated based on the change in Tinnitus Handicap Inventory (THI) scores. A higher score indicates greater interference of tinnitus with quality of life. Treatment response is defined as a reduction in the THI score of \>7 points from the baseline assessment after 3 months of treatment, based on the internationally recognized Minimal Clinically Important Difference (MCID) threshold. Calculation Formula: Tinnitus Improvement Response Rate (%) = (Number of Responders / Total Number of Cases in the Corresponding Group) × 100%

    Before treatment and at the end of the 3-month treatment period

Secondary Outcomes (11)

  • Change in Self-Perceived Tinnitus Loudness assessed by Visual Analogue Scale (VAS) Score

    Baseline, Month 3, Month 6, Month 12

  • Change in Tinnitus Loudness Matching Threshold

    Baseline, Month 3, Month 6, Month 12

  • Number of Participants with Treatment-Related Adverse Events

    From Baseline through Month 3

  • Change in Beck Anxiety Inventory (BAI) Standardized Score

    Baseline, Month 3, Month 6, Month 12

  • Change in Beck Depression Inventory (BDI) Total Score

    Baseline, Month 3, Month 6, Month 12

  • +6 more secondary outcomes

Study Arms (2)

taVNS + TMNMT

EXPERIMENTAL

transcutaneous auricular vagus nerve stimulation combined with tailor-made notched music training therapy

Device: transcutaneous auricular vagus nerve stimulation combined with tailor-made notched music training therapy

TRT

ACTIVE COMPARATOR

Tinnitus Retraining Therapy

Device: tinnitus retraining therapy

Interventions

This group receives standard Tinnitus Retraining Therapy (TRT) using the same device platform, but without active microcurrent output. Therapy includes structured counseling and sound therapy, where broadband natural sounds are delivered at a individually set "mixing" level via the device. Daily sound exposure totals 2 hours over 3 months, supported by initial education and follow-up counseling sessions focused on habituation and cognitive restructuring.

TRT

This group receives combined transcutaneous auricular vagus nerve stimulation (taVNS) and tailor-made notched music training (TMNMT) delivered through a single, registered Class II medical device. The device synchronously administers taVNS (0.1 Hz, pulse train, 0.5-10 mA, titrated below individual pain threshold) and delivers TMNMT via integrated, phase-synchronized algorithms. The notched music is centered at the patient's tinnitus frequency with a ½-octave bandwidth. Treatment consists of 30-minute sessions, four times daily for 3 months.

taVNS + TMNMT

Eligibility Criteria

Age18 Years - 70 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients whose primary complaint is tinnitus and who seek medical care for this reason
  • Patients diagnosed with chronic tinnitus for more than 6 months
  • Age between 18 and 70 years
  • Tinnitus frequency within the range of 125-8000 Hz
  • Hearing threshold not exceeding 70 dB HL
  • Tinnitus Handicap Inventory (THI) score ≥ 38 points.

You may not qualify if:

  • Patients with conductive hearing loss, history of middle ear surgery, pulsatile tinnitus due to vascular malformations, or tinnitus associated with Meniere's disease
  • History of head trauma, central nervous system disorders, psychiatric disorders, or substance abuse/dependence
  • Patients unwilling or unable to comply with the study protocol requirements
  • Patients with space-occupying lesions in the peripheral auditory pathway or central nervous system (e.g., acoustic neuroma, middle ear cholesteatoma, meningioma) as identified by imaging studies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China

Location

Study Officials

  • Yuexin Cai

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2026

First Posted

March 13, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

March 31, 2030

Study Completion (Estimated)

March 31, 2030

Last Updated

March 13, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) from this study will not be shared due to privacy concerns and ethical restrictions related to patient confidentiality.

Locations